Phar­ma gi­ants tout AI tools as high pri­or­i­ty in half-year earn­ings re­ports

Big Phar­ma com­pa­nies are catch­ing the ar­ti­fi­cial in­tel­li­gence wave, ev­i­denced by a num­ber of drug­mak­ers’ com­ments in their half-year earn­ings re­ports this week.

A hand­ful of com­pa­nies high­light­ed their AI ef­forts across drug de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion, in­clud­ing As­traZeneca, Roche, Take­da and GSK so far. Con­sult­ing firm McK­in­sey & Com­pa­ny re­port­ed a “rapid rise” in phar­ma part­ner­ships with AI com­pa­nies back in Oc­to­ber, iden­ti­fy­ing near­ly 270 com­pa­nies in the AI-dri­ven drug dis­cov­ery space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER